Abacus Bioscience Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 7

Abacus Bioscience General Information

Description

Developer of novel immune treatments intended to assist in treating cancer and chronic viral diseases. The company's treatments are based upon the delivery of antigens capable of evoking protective immunity to a receptor expressed on two major classes of cells that program immune responses, enabling medical professionals to use a broad-based platform that can plug and play with multiple cancer or viral antigens.

Contact Information

Website
www.abacusbioscience.com
Formerly Known As
Shilshole Bioscience
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1616 Eastlake Avenue East
  • Unit 208
  • Seattle, WA 98102
  • United States
+1 (425)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 1616 Eastlake Avenue East
  • Unit 208
  • Seattle, WA 98102
  • United States
+1 (425)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Abacus Bioscience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Secondary Transaction - Private Completed Generating Revenue
3. Later Stage VC (Series A) 15-Jun-2024 Completed Generating Revenue
2. Grant 01-Jun-2022 $398K $150K Completed Generating Revenue
1. Early Stage VC 06-Feb-2019 $150K $150K Completed Generating Revenue
To view Abacus Bioscience’s complete valuation and funding history, request access »

Abacus Bioscience Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Seed-4
Seed-3
Seed-2 348,902 $0.001000 $0.56 $0.56 1x $0.56 1.76%
Seed-1 4,633,307 $0.001000 $0.76 $0.76 1x $0.76 23.33%
To view Abacus Bioscience’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Abacus Bioscience Patents

  • 11

    Total Documents Applications and Grants

  • Total Patents Families

  • 10

    Granted

  • 1

    Pending

  • Expiring in next 12 mo

Abacus Bioscience Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026206782-A1 Humanized cd180 antibodies and uses thereof Pending 22-Mar-2025
US-20200345838-A1 A therapeutic vaccine for hepatitis b virus (hbv) using the hbv pres1 and/or pres2, and/or s-hbsag regions of the hbv envelope protein Active 16-Nov-2017
US-11389532-B2 Therapeutic vaccine for hepatitis b virus (hbv) using the hbv pres1 and/or pres2, and/or s-hbsag regions of the hbv envelope protein Active 16-Nov-2017
US-12285482-B2 Therapeutic vaccine for hepatitis b virus (hbv) using the hbv pres1 and/or pres2, and/or s-hbsag regions of the hbv envelope protein Active 16-Nov-2017
US-20230053634-A1 Therapeutic vaccine for hepatitis b virus (hbv) using the hbv pres1 and/or pres2, and/or s-hbsag regions of the hbv envelope protein Active 16-Nov-2017 C07K16/2896
To view Abacus Bioscience’s complete patent history, request access »

Abacus Bioscience Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Abacus Bioscience Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alexandria Venture Investments Venture Capital Minority
Alliance of Angels Angel Group Minority
Pack Ventures Venture Capital Minority
Seagen Corporation Minority
Whetstone Ventures Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Ready to get started?

Request a free trial

Abacus Bioscience FAQs

  • When was Abacus Bioscience founded?

    Abacus Bioscience was founded in 2015.

  • Where is Abacus Bioscience headquartered?

    Abacus Bioscience is headquartered in Seattle, WA.

  • What is the size of Abacus Bioscience?

    Abacus Bioscience has 7 total employees.

  • What industry is Abacus Bioscience in?

    Abacus Bioscience’s primary industry is Drug Discovery.

  • Is Abacus Bioscience a private or public company?

    Abacus Bioscience is a Private company.

  • What is Abacus Bioscience’s current revenue?

    The current revenue for Abacus Bioscience is .

  • How much funding has Abacus Bioscience raised over time?

    Abacus Bioscience has raised $4.56M.

  • Who are Abacus Bioscience’s investors?

    Alexandria Venture Investments, Alliance of Angels, Pack Ventures, Seagen, and Whetstone Ventures are 5 of 7 investors who have invested in Abacus Bioscience.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process